• Raising up to A$2 million through a Share Purchase Plan
• Shares offered at A$0.027, a 15.6% discount to last closing price
• Funds to be used for clinical trial readouts and licensing discussions

Syntara Ltd is offering eligible shareholders the opportunity to participate in a Share Purchase Plan (SPP) to raise up to A$2 million. The SPP shares will be issued at A$0.027 per share, representing a 15.6% discount to the last closing price and a 17.6% discount to the 5-day VWAP. Participation in the SPP is voluntary and open to shareholders with a registered address in Australia or New Zealand as of the record date. Eligible shareholders can apply for a minimum of A$1,000 and up to a maximum of A$30,000 worth of new shares. The net funds raised from the SPP will be used to fund five key clinical trial readouts and to progress licensing discussions across Syntara's pipeline. The Placement and SPP are collectively referred to as the Capital Raising, with the Placement proceeds providing a cash runway to Q3 2027. Syntara is targeting to raise approximately A$2 million under the SPP, but has the discretion to accept higher or lower amounts depending on demand.